Plain-English translation of NCT07607964 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medicine called designed to help people with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) who haven't responded well to other treatments. Researchers want to understand how the medication moves through your body, how it works, and whether it is safe. This is an early-stage study, so the main goal is to gather safety and effectiveness information.
Both SLE and RA are serious autoimmune diseases where the body's immune system attacks itself, causing pain, swelling, and organ damage. Many people don't respond well enough to currently available treatments, so this new treatment aims to offer another option for patients who need better control of their disease.
You likely qualify if…
You likely don't qualify if…
You will receive a single dose of the medication—either as an intravenous infusion (through an IV in your arm) or as a subcutaneous injection (under the skin)—depending on which group you're assigned to. Your participation will span approximately 425 days (about 14 months) and include a screening period, the treatment day, and regular follow-up visits at a clinic or hospital for about a year. During visits, you'll have blood tests, physical exams, and check-ins to monitor for side effects and measure how the treatment is working.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States